MetaCap

China SXT Pharmaceuticals Inc. (SXTC)

NASDAQ: SXTCHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.65+0.055 (+2.12%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SXTC stock chart

Technical analysis

Key statistics

All statistics
Market cap
$273.95K
EPS (TTM)
-$73,040.00
52-week range
2.52 – 8,376,000.00
Day range
2.63 – 2.76
Volume / Avg
24.95K / 234.25K
Beta
—

52-week range

$2.52$8,376,000.00

SXTC stock today

On Nov 20, SXTC ended the session at $2.65, adding $0.055 (2.12%), versus the S&P 500's 3.70% decline. Trading was light, with 24.95K shares changing hands, about 11% of the average daily volume. At this level, SXTC sits near the bottom of its 52-week range of $2.52 to $8,376,000.00: 100.0% below the high and 4.9% above the low.

China SXT Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$73,040.00), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About China SXT Pharmaceuticals

Company profile

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Feng Zhou
Headquarters
Taizhou
Employees
56
IPO year
2019

Financial highlights

Full financials

In fiscal 2026, China SXT Pharmaceuticals generated $1.1 million in revenue, down 34.6% from fiscal 2025, its first annual decline since 2025. China SXT Pharmaceuticals reported a net loss of $6.2 million, compared with a loss of $3.3 million a year earlier. Gross margin was 21.9% (up from 21.1%) and operating margin -625.9%.

China SXT Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024FY 2023FY 2022
Revenue$1.14M$1.74M$1.93M$1.97M$2.60M
Growth-34.63%-9.73%-2.19%-24.23%-45.53%
Net income$-6.21M$-3.30M$-3.10M$-5.93M$-5.74M
EPS (diluted)$-9.13$-348.17$-4,285.66$-177.84$-137.92

SXTC news

All SXTC news

China SXT Pharmaceuticals peers

Health Care sector
SXTC peer companies
CompanyPrice% ChgMarket capCompare
CDTCDT Equity Inc.0.23-13.89%$437.03Kvs SXTC
SPRCSciSparc Ltd.0.1955-34.83%$481.60Kvs SXTC
LSTALisata Therapeutics Inc.0.8989-1.22%$647.45Kvs SXTC
OGENOragenics Inc.0.157-8.72%$708.38Kvs SXTC
MTNBMatinas Biopharma Holdings Inc.0.7999-1.26%$890.71Kvs SXTC
BDRXBiodexa Pharmaceuticals plc American Depositary Shs1.88-3.85%$982.95Kvs SXTC
GOVXGeoVax Labs Inc.1.81-5.24%$985.46Kvs SXTC
ARTLArtelo Biosciences Inc.1.39-4.14%$1.30Mvs SXTC

Indexes, lists and sector

China SXT Pharmaceuticals stock FAQ

What is China SXT Pharmaceuticals's stock price today?

SXTC last traded at $2.65 as of Nov 20, 4:00 PM EST, up 2.12% on the day. Prices are delayed at least 15 minutes.

Does China SXT Pharmaceuticals pay a dividend?

No. China SXT Pharmaceuticals does not currently pay a regular cash dividend.

Who is China SXT Pharmaceuticals's CEO?

Mr. Feng Zhou is the chief executive officer of China SXT Pharmaceuticals Inc., which has about 56 employees.

Has SXTC ever split its stock?

Yes. The most recent SXTC stock split was a 1-for-100 split on Oct 26, 2026.

What is the SXTC 52-week high?

The 52-week high for SXTC is $8,376,000.00 and the 52-week low is $2.52. The stock is currently 100.0% below its high.

Compare SXTC